cefotetan

Trade name: cefotan

Small moleculeapproved

Approved

Dec 27, 1985

Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. It is FDA approved for the treatment of urinary tract infection, lower respiratory tract infection, skin and skin structure infections, gynecologic infection, intra-abdominal infection, and bone and joint infection; and for prophylaxis of postoperative infection. The bactericidal action of cefotetan results from inhibition of cell wall synthesis. The methoxy group in the 7-alpha position provides cefotetan with a high degree of stability in the presence of beta-lactamases including both penicillinases and cephalosporinase of gram-negative bacteria. Common adverse reactions include diarrhea and nausea. As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels. — NCATS

Clinical trial activity

4 trials · 4 clinical orgs · 6 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Apr 1, 2002 (NCT00090272)

Timeline

1980s

  1. Dec 27, 1985

    Teligent Pharmaceuticals — Earliest FDA Approval

  2. Dec 27, 1985

    Pharmaceutical Associates — Marketing Organization

  3. Dec 27, 1985

    Teligent Pharmaceuticals — NDA Organization

  4. Dec 27, 1985

    Teligent Pharmaceuticals — NDA Secondary Org

  5. Dec 27, 1985

    Pharmaceutical Associates — NDA Secondary Org

1990s

  1. Apr 29, 1993

    Teligent Pharmaceuticals — Marketing Organization

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

  2. Aug 9, 2007

    B. Braun — NDA Secondary Org

  3. Aug 9, 2007

    Fresenius — Marketing Organization

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Oct 26, 2011

    Hikma — Marketing Organization

  3. Oct 26, 2011

    West-Ward Pharmaceutical — Marketing Organization

  4. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 27, 1985

Chemistry & pharmacology

Loading structure…

SMILES

CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)O)S2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
Mol. weight
575.63 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • (6r,7s)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
  • (6r,7s)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
  • apacef
  • cefotan
  • cefotan
  • cefotan
  • cefotetan
  • cefotetan
  • cefotetan
  • cefotetan
  • cefotetan
  • cefotetan
  • cefotetan
  • cefotetan
  • cefotetan
  • cefotetan
  • cefotetan disodium
  • cefotetan disodium
  • cefotetan disodium
  • cefotetan disodium
  • cefotetan sodium
  • cefotetan sodium
  • cefotetanum
  • cefotetanum
  • ici-156834
  • ici-156834
  • yamatetan
  • yamatetan
  • ym-09330
  • ym-09330

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04726046Phase 1Apr 1, 2014Chonbuk National University
NCT01220661Phase 2Oct 1, 2010National Cancer Center, Korea
NCT00186082N/ASep 1, 2003Stanford University
NCT00090272Phase 3Apr 1, 2002Merck
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Chonbuk National UniversityAcademic/Hospital1112014
MerckFor profit1112002
National Cancer Center, KoreaGovernment1112010
Stanford UniversityAcademic/Hospital1112003
4 organizations
Page 1 / 1

Marketing (9)

OrganizationOrg typeRelationshipDate
B. BraunFor profitNDA2Aug 9, 2007
FreseniusFor profitMKTGAug 9, 2007
HikmaFor profitMKTGOct 26, 2011
Pharmaceutical AssociatesFor profitMKTGDec 27, 1985
Pharmaceutical AssociatesFor profitNDA2Dec 27, 1985
Teligent PharmaceuticalsFor profitNDADec 27, 1985
Teligent PharmaceuticalsFor profitNDA2Dec 27, 1985
Teligent PharmaceuticalsFor profitMKTGApr 29, 1993
West-Ward PharmaceuticalFor profitMKTGOct 26, 2011